Intellia Plans IPO, Signs Gene-Editing Pact With Regeneron
This article was originally published in Scrip
Intellia Therapeutics, a US-based developer of human medicines based on the gene editing technology CRISPR-Cas9, has filed an IPO prospectus while also announcing a licensing and collaboration agreement with Regeneron Pharmaceuticals.
You may also be interested in...
Finance Watch: Four IPOs In One Week, And Legend Is Year’s Largest So Far
Public Company Edition: Legend Biotech raised $424m in its US public market debut. Also, Pfizer commits up to $500m for equity investments and Allogene capitalizes on ASCO with a $550m offering.
Deal Watch: Chinook To Go Public Via Reverse Merger With Troubled Aduro
Focused on precision medicine for renal disease, Chinook gets Aduro’s Nasdaq listing and starting capital of $200m. During a wave of modest-sized M&A deals, Tetra finds buyer, Tetraphase gets competing bids.
CRISPR Therapeutics, Vertex Initiate First Industry-Sponsored Trial – What’s Next?
CRISPR Therapeutics and Vertex initiated the first human study of CRISPR gene-editing technology with an industry sponsor, following an investigator-sponsored study initiated in China two years ago. These are not the first gene-editing trials, but they're important milestones for the CRISPR field.